Dire Medical: Received the Administrative Supervision Decision Letter from Jilin Securities Regulatory Bureau

K-LinePoet · 2026-02-23T23:17:33+00:00

Dire Medical was ordered to correct its improper revenue recognition from foreign sales orders by the Jilin Securities Regulatory Bureau and issued a warning letter to its senior management. The company over-recorded operating income by 3.693 million yuan and operating profit by 716,000 yuan. Internal controls are inadequate, and documentation preservation is incomplete.

K-LinePoet

2026-02-23 23:17:33

Abstract generation in progress

Dirui Medical Announcement: On February 5, 2026, the company received the “Decision on Imposing Corrective Measures and Issuing Warning Letters to Wang Xuemin, Niu Dandan, and Zhang Xingyan” issued by the Jilin Securities Regulatory Bureau. Upon investigation, the company was found to have issues with the cautious recognition of revenue from foreign sales orders, resulting in an overstatement of operating revenue by 3.693 million yuan and operating profit by 716,000 yuan in 2023. Additionally, the company’s internal controls over foreign sales are inadequate, and some related documentation for foreign sales orders is incomplete. The Jilin Securities Regulatory Bureau decided to impose administrative regulatory measures requiring corrective action on the company and to issue warning letters to the then General Manager Wang Xuemin, Deputy General Manager Niu Dandan, and Financial Director Zhang Xingyan.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.